These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344 [TBL] [Abstract][Full Text] [Related]
7. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes. Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B. Iman M; Huang Z; Szoka FC; Jaafari MR Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963 [TBL] [Abstract][Full Text] [Related]
9. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606 [TBL] [Abstract][Full Text] [Related]
11. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B. Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824 [TBL] [Abstract][Full Text] [Related]
12. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279 [TBL] [Abstract][Full Text] [Related]
13. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis. Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075 [TBL] [Abstract][Full Text] [Related]
14. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. Italia JL; Kumar MN; Carter KC J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479 [TBL] [Abstract][Full Text] [Related]
15. Biodistribution and Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182 [TBL] [Abstract][Full Text] [Related]
16. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510 [TBL] [Abstract][Full Text] [Related]
17. Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity. Zahid F; Batool S; Ud-Din F; Ali Z; Nabi M; Khan S; Salman O; Khan GM AAPS PharmSciTech; 2022 Aug; 23(6):226. PubMed ID: 35970966 [TBL] [Abstract][Full Text] [Related]
18. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models. Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889 [TBL] [Abstract][Full Text] [Related]
20. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major. Mehrizi TZ; Ardestani MS; Khamesipour A; Hoseini MHM; Mosaffa N; Anissian A; Ramezani A J Mater Sci Mater Med; 2018 Jul; 29(8):125. PubMed ID: 30056571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]